MGO One Seven’s Esperion Therapeutics ESPR Stock Holding History

MGO One Seven’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-250	Closed	-$11K	–	761
2018 Q4	$11K	Buy	+250	New	+$12K	﹤0.01%	1109

Other funds holding ESPR

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

MGO One Seven's ESPR Position: Q1 2019 in Review

MGO One Seven sold out of Esperion Therapeutics (ESPR) in Q1 2019, closing a stake of 250 shares — an estimated $11K sold.

MGO One Seven first reported a position in ESPR in Q4 2018 and held it in 1 quarter. The position peaked at $11K in Q4 2018. 163 funds tracked by Wall St. Rank hold ESPR as of Q1 2019.

MGO One Seven reported no remaining Esperion Therapeutics position as of Q1 2019 after selling out during the quarter.
MGO One Seven sold 250 Esperion Therapeutics shares in Q1 2019, an estimated $11K.
MGO One Seven first reported a position in Esperion Therapeutics in Q4 2018 and held it in 1 quarter.
MGO One Seven's Esperion Therapeutics position peaked at $11K in Q4 2018.
163 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2019.

Based on MGO One Seven's 13F filing for Q1 2019, filed 9 Apr 2019.